SCHEMBL15569129

SCHEMBL15569129

NC(=O)C(Nc1cncc(-c2cc(Cl)ccc2F)c1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.46
XDH P47989 3/20 0.43
SLC22A12 Q96S37 3/20 0.43
MAPK1 P28482 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C9 P11712 2/20 0.41
PDGFRA P16234 1/20 0.41
MAPKAPK2 P49137 1/20 0.41
RPS6KA1 Q15418 1/20 0.41
AURKB Q96GD4 1/20 0.41
CSNK1G1 Q9HCP0 1/20 0.41
CTSA P10619 1/20 0.40
FDPS P14324 1/20 0.39
MAPK10 P53779 1/20 0.39
S1PR1 P21453 1/20 0.39
S1PR3 Q99500 1/20 0.39
GRM5 P41594 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15569128 1.00 CNR1 (0.46) CNR1XDHSLC22A12MAPK1CYP3A4
SCHEMBL15569443 0.93 MDM2 (0.44) CNR1XDHSLC22A12GRM5MDM2
SCHEMBL15570006 0.92 SYK (0.44) CNR1XDHSLC22A12MAPK1CYP2C9
SCHEMBL15569783 0.91 CNR1 (0.47) CNR1XDHSLC22A12CTSAFDPS
SCHEMBL15569781 0.91 CNR1 (0.47) CNR1XDHSLC22A12CTSAFDPS
SCHEMBL15569748 0.89 SYK (0.41) CNR1XDHSLC22A12CTSAGRM5
SCHEMBL15569152 0.89 XDH (0.44) CNR1XDHSLC22A12MAPK1CYP3A4
SCHEMBL15568823 0.89 SYK (0.44) CNR1XDHSLC22A12MAPK1CYP2C9
SCHEMBL15569792 0.88 CNR1 (0.42) CNR1XDHSLC22A12CTSAFDPS
SCHEMBL15569177 0.87 CTSA (0.49) XDHSLC22A12MAPK1CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9458106-B2 Phenyl-pyridine/pyrazine amides for the treatment of cancer HOFFMANN-LA ROCHE INC. (US) 2016-10-04 US disclosed
EP-2888232-A1 NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2015-07-01 EP disclosed
US-20150158815-A1 NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER HOFFMANN-LA ROCHE INC. (US) 2015-06-11 US disclosed
WO-2014029726-A1 NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2014-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158815-A1 NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER TP53, RB1, HCCS CNR1 338/4885XDH 1992/4885SLC22A12 1361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.